MedTech Acquisition (MedTech Acquisition) Debt-to-Equity : -1.08 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Debt-to-Equity?

MedTech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.33 Mil. MedTech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. MedTech Acquisition's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-3.07 Mil. MedTech Acquisition's debt to equity for the quarter that ended in Jun. 2023 was -1.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MedTech Acquisition's Debt-to-Equity or its related term are showing as below:

MTACU' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.08 Med: 0.01 Max: 1.79
Current: -1.08

During the past 3 years, the highest Debt-to-Equity Ratio of MedTech Acquisition was 1.79. The lowest was -1.08. And the median was 0.01.

MTACU's Debt-to-Equity is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.13 vs MTACU: -1.08

MedTech Acquisition Debt-to-Equity Historical Data

The historical data trend for MedTech Acquisition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition Debt-to-Equity Chart

MedTech Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Equity

0.01

0.36

MedTech Acquisition Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial							0.01	0.01	0.36	0.48	-1.08

Competitive Comparison of MedTech Acquisition's Debt-to-Equity

For the Shell Companies subindustry, MedTech Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedTech Acquisition's Debt-to-Equity Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's Debt-to-Equity falls into.

MedTech Acquisition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MedTech Acquisition's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.983	+	1.341)	/	6.533
	=	0.36

MedTech Acquisition's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.331	+	0)	/	-3.074
	=	-1.08

MedTech Acquisition (NAS:MTACU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MedTech Acquisition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MedTech Acquisition (MedTech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

48 Maple Avenue, Greenwich, CT, USA, 06830

Website

MedTech Acquisition Corp is a blank check company.

Executives

Magnetar Financial Llc	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc	10 percent owner	1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman	10 percent owner	C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell	director	222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin	director, 10 percent owner, officer: Chief Financial Officer
Karim Karti	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey	director, 10 percent owner, officer: Chief Executive Officer	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss	officer: Chief Admin Officer and Sec.	585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022